Dublin, Feb. 13, 2020 (GLOBE NEWSWIRE) -- The "Hemophilia A - Epidemiology - 2030" report has been added to ResearchAndMarkets.com's offering.
The disease epidemiology covered in this report provides historical as well as forecasted epidemiology [segmented by Total Prevalence of Hemophilia A, Diagnosed and Treated Prevalent Population of Hemophilia A, Severity-Specific Prevalence of Hemophilia A, and Prevalence of Hemophilia A with Inhibitors and Without Inhibitors] scenario of Hemophilia A in the 7MM Countries covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.
Report Scope
- The report covers a detailed overview of Hemophilia A explaining its causes, symptoms, classification, and pathophysiology.
- The report provides insight about the historical and forecasted patient pool for seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan.
- The report helps to recognize the growth opportunities in the 7MM countries with respect to the patient population.
- The report provides the segmentation of the disease epidemiology by Total Prevalence of Hemophilia A, Diagnosed and Treated Prevalent Population of Hemophilia A, Severity-Specific Prevalence of Hemophilia A, and Prevalence of Hemophilia A with Inhibitors and Without Inhibitors.
Key Report Features
- 11-Year Forecast
- 7MM Coverage
- Total Prevalence of Hemophilia A
- Diagnosed and Treated Prevalent Population of Hemophilia A
- Severity-Specific Prevalence of Hemophilia A
- Prevalence of Hemophilia A with Inhibitors and without Inhibitors
Report Assessment
- Patient segmentation
- Disease risk and burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
Key Topics Covered:
1. Key Insights
2. Executive Summary
3. Hemophilia A: Disease Background and Overview
3.1. Introduction
3.2. Diagnosis of Hemophilia A
3.2.1. Establishing the Diagnosis
3.2.2. Molecular Genetic Testing
3.2.3. Screening Tests
3.2.4. Clotting Factor Tests
3.2.5. Inhibitor Testing
4. Epidemiology and Patient Population
4.1. Epidemiology Key Findings
4.2. Assumptions and Rationale: 7MM
4.3. Epidemiology Scenario: 7MM
4.3.1. Total Diagnosed Prevalence of Hemophilia A in the 7MM
4.3.2. Severity- Specific Prevalence of Hemophilia A in the 7MM
4.3.3. Prevalence of Hemophilia A with or without Inhibitors the 7MM
5. United States Epidemiology
6. EU-5 Country-wise Epidemiology
7. Japan Epidemiology
8. Appendix
For more information about this report visit https://www.researchandmarkets.com/r/5ig6id
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.